Related Experiment Videos
Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with
J Conard1, A Basdevant, J L Thomas
1Department of Hemostasis, Hotel-Dieu, Paris, France.
Objective:
To assess the effects of oral E2 replacement therapy combined with nomegestrol acetate, a 19-norprogesterone derivative, on cardiovascular risk factors.
Design:
A double-blind randomized prospective study comparing the effect of a placebo and two oral E2-nomegestrol acetate combinations (1 mg-2.5 mg and 1.5 mg-3.75 mg) over a three-cycle trial.
Setting:
Department of Internal Medicine and Nutrition, Hotel-Dieu, Paris, France.
Patients:
Fifty-seven nonhysterectomized women with natural menopause.
Main Outcome Measures:
Blood pressure, renin substrate, glucose, total cholesterol, high-density and low-density lipoprotein cholesterol, triglycerides, apoproteins A1 and B, lipoprotein(a), antithrombin III, fibrinogen, plasminogen, prothrombin fragment 1 + 2, protein C, and total and free protein S.
Results:
Both treatments significantly reduced menopausal complaints, total cholesterol, low-density lipoprotein cholesterol and lipoprotein(a). Treatment with the 1.5 mg-3.75 mg combination resulted in a significant increase in apolipoprotein A1. No significant change were observed in other parameters.
Conclusions:
Sequentially combined with oral E2 in hormone replacement therapy, nomegestrol acetate had favorable effects on plasma lipids and lipoproteins. This nonandrogenic progestin decreased lipoprotein(a) levels as observed previously with medroxyprogesterone acetate combined with conjugated equine estrogens.